MTAP and non-small cell lung carcinoma: Predictors of immunotherapy efficacy were higher in MTAP‐intact versus MTAP‐lost NSCLC including tumor mutational burden (9.4 vs. 8.6 mut/Mb, p = 0.001) and low (30% vs. 28%, p = 0.01) and high PD‐L1 (32% vs. 30%, p = 0.01) expression.